Yıl: 2020 Cilt: 3 Sayı: 3 Sayfa Aralığı: 133 - 140 Metin Dili: İngilizce DOI: 10.30714/j-ebr.2020361048 İndeks Tarihi: 08-12-2020

Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients

Öz:
Aim: To evaluate the effectiveness of contrast-induced acute kidney injury (CI-AKI) prophylaxisretrospectively, using calcium channel blockers (CCB) before and after contrast exposure andcomparing them with patients using angiotensin converting enzyme inhibitors (ACEI), which has notbeen explored by many studies.Methods: The study was performed in Afyon Kocatepe University, Faculty of Medicine ResearchHospital, Cardiology Department between January 2014 and June 2016. Eighty patients usingdihydropyridine (amlodipine 10 mg), non-dihydropyridine (diltiazem 60 mg) CCB or ACEI in theform of monotherapy before coronary angiography were included.Results: In the CCB and ACEI group, CI-AKI development rates were 15.7% (n=8) and 24.1% (n=7),respectively (p = 0.383; Fisher's exact test). When the CCB group was evaluated as dihydropyridineand non-dihydropyridine subsets, CI-AKI development rates were found to be similar as well (p =0.445; Fisher’s exact test) in each subset.Conclusion: In our study, we evaluated one of today's important dilemma; the methods related to theprophylaxis of CI-AKI. Our study shows that there is no difference in the development of CI-AKIbetween patients using the calcium channel blocker group drugs and ACEI as monotherapy. However,in our study, the mean age of patients using CCB was significantly higher than the group using ACEI.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • [1]Vergadis C, Festas G, Spathi E, et al. Methods for Reducing Contrast Use and Avoiding Acute Kidney Injury During Endovascular Procedures. Curr Pharm Des. 2019; 25(44): 4648-55.
  • [2]Persson PB, Tepel M. Contrast mediuminduced nephropathy: the pathophysiology. Kidney Int Suppl. 2006;(100): S8-10.
  • [3]Yang D, Yang D, Jia R, et al. Na+/Ca2+ exchange inhibitor, KB-R7943, attenuates contrast-induced acute kidney injury. J Nephrol. 2013;26(5): 877-85.
  • [4]Zhao K, Gao Q, Zong C, et al. Cordyceps sinensis prevents contrast-induced nephropathy in diabetic rats: its underlying mechanism. Int J Clin Exp Pathol. 2018; 11(12): 5571-80.
  • [5]Hiremath S, Velez JCQ. Preventing a nonexistent entity: the curious case of contrast and acute kidney injury. Curr Opin Nephrol Hypertens. 2020; 29(1): 152-60.
  • [6]Briguori C, Tavano D, Colombo A. Contrast agent--associated nephrotoxicity. Prog Cardiovasc Dis. 2003; 45(6): 493-503.
  • [7]Andreucci M, Faga T, Serra R, et al. Update on the renal toxicity of iodinated contrast drugs used in clinical medicine. Drug Healthc Patient Saf. 2017; 9: 25-37.
  • [8]Andreucci M, Faga T, Pisani A, et al. Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors. ScientificWorldJournal. 2014; 2014: 823169.
  • [9]Neumayer HH, Junge W, Kufner A, et al. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant. 1989; 4(12): 1030-36.
  • [10]Russo D, Testa A, Della Volpe L, et al. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron. 1990; 55(3): 254-57.
  • [11]Khoury Z, Schlicht JR, Como J, et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy. 1995; 15(1): 59- 65.
  • [12]Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994; 331(21): 1416-20.
  • [13]Spangberg-Viklund B, Berglund J, Nikonoff T, et al. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scand J Urol Nephrol. 1996; 30(1): 63-68.
  • [14]Beyazal H, Caliskan Z , Utac C. Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy. Ren Fail. 2014; 36(3): 351-55.
  • [15]Aritomi S, Harada E, Sugino K, et al. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneouslyhypertensive rats. Clin Exp Pharmacol Physiol. 2015; 42(4): 344-52.
  • [16]Duan SB, Liu FY, Luo JA, et al. Nephrotoxicity of high- and low-osmolar contrast media. The protective role of amlodipine in a rat model. Acta Radiol. 2000; 41(5): 503-7.
  • [17]Fan YY, Kohno M, Nakano D, et al. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte. J Hypertens. 2010; 28(5): 1034-43.
  • [18]Arici M, Usalan C, Altun B, et al. Radiocontrast-induced nephrotoxicity and urinary alpha-glutathione S-transferase levels: effect of amlodipine administration. Int Urol Nephrol. 2003; 35(2): 255-61.
  • [19]Gupta RK, Kapoor A, Tewari S, et al. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J. 1999; 51(5): 521-26.
  • [20]Toprak O, Cirit M, Bayata S, et al. The effect of pre-procedural captopril on contrastinduced nephropathy in patients who underwent coronary angiography. Anadolu Kardiyol Derg. 2003; 3(2): 98-103.
  • [21]Hui H, Li K, Li Z, et al. Protective effect of amlodipine against contrast agent-induced renal injury in elderly patients with coronary heart disease. Nan Fang Yi Ke Da Xue Xue Bao. 2012; 32(11): 1580-83.
  • [22]Oguzhan N, Cilan H, Sipahioglu M, et al. The lack of benefit of a combination of an angiotensin receptor blocker and calcium channel blocker on contrast-induced nephropathy in patients with chronic kidney disease. Ren Fail. 2013; 35(4): 434-39.
  • [23]Davidson CJ , Hlatky M, Morris KG , et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med. 1989; 110(2): 119-24.
APA Atak B, ULU M, kazan s, polat m (2020). Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients. , 133 - 140. 10.30714/j-ebr.2020361048
Chicago Atak Burcin Meryem,ULU MEMNUNE SENA,kazan sinan,polat mehmet Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients. (2020): 133 - 140. 10.30714/j-ebr.2020361048
MLA Atak Burcin Meryem,ULU MEMNUNE SENA,kazan sinan,polat mehmet Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients. , 2020, ss.133 - 140. 10.30714/j-ebr.2020361048
AMA Atak B,ULU M,kazan s,polat m Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients. . 2020; 133 - 140. 10.30714/j-ebr.2020361048
Vancouver Atak B,ULU M,kazan s,polat m Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients. . 2020; 133 - 140. 10.30714/j-ebr.2020361048
IEEE Atak B,ULU M,kazan s,polat m "Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients." , ss.133 - 140, 2020. 10.30714/j-ebr.2020361048
ISNAD Atak, Burcin Meryem vd. "Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients". (2020), 133-140. https://doi.org/10.30714/j-ebr.2020361048
APA Atak B, ULU M, kazan s, polat m (2020). Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients. Experimental Biomedical Research, 3(3), 133 - 140. 10.30714/j-ebr.2020361048
Chicago Atak Burcin Meryem,ULU MEMNUNE SENA,kazan sinan,polat mehmet Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients. Experimental Biomedical Research 3, no.3 (2020): 133 - 140. 10.30714/j-ebr.2020361048
MLA Atak Burcin Meryem,ULU MEMNUNE SENA,kazan sinan,polat mehmet Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients. Experimental Biomedical Research, vol.3, no.3, 2020, ss.133 - 140. 10.30714/j-ebr.2020361048
AMA Atak B,ULU M,kazan s,polat m Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients. Experimental Biomedical Research. 2020; 3(3): 133 - 140. 10.30714/j-ebr.2020361048
Vancouver Atak B,ULU M,kazan s,polat m Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients. Experimental Biomedical Research. 2020; 3(3): 133 - 140. 10.30714/j-ebr.2020361048
IEEE Atak B,ULU M,kazan s,polat m "Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients." Experimental Biomedical Research, 3, ss.133 - 140, 2020. 10.30714/j-ebr.2020361048
ISNAD Atak, Burcin Meryem vd. "Evaluation of renoprotective effect of calcium channel blockers in coronary angiography patients". Experimental Biomedical Research 3/3 (2020), 133-140. https://doi.org/10.30714/j-ebr.2020361048